MiRus valuation, funding and investors
MiRus works in medical device development and manufacturing, based in Marietta, United States. Founded in 2015, it has about 135 employees.
VALUATION · TODAY
$17.46B +6% after Growth
Range $11.08B – $28.23B · Grade BTODAY
+12 MO
$10.00B
$20.00B
$30.00B
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Growth $65.0M
Growth $1.50B
ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then
HEADCOUNT · TODAY135 employees
+4%6m growth
+9%1y growth
+23%2y growth
50
100
150
Data from Apr 2022
Predicted in 1 yr $18.55B +6% vs today
Predicted next raise $1.67B if a round comes
Winding-down probability 0%
- Last round
- Growth · $1.50B · May 2026
- Valuation at last round
- $16.67B · implied
- Headcount
- 135 · up
- Grade
- B
- Founded
- 2015
MiRus valuation today
VCMC values MiRus at $17.5B today, with a range of $11.1B to $28.2B and a grade of B. The valuation starts from its last funding round, a growth round in May 2026.
Valuation by date (145 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2015 | $5.25M | $1.91M – $14.4M | $5.51M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2015 | $5.28M | $1.92M – $14.5M | $5.53M (+5%) | before first round | – | unknown | D | 0% |
| 1 Mar 2015 | $5.29M | $1.93M – $14.5M | $5.55M (+5%) | before first round | – | unknown | D | 0% |
| 1 Apr 2015 | $5.32M | $1.93M – $14.6M | $5.57M (+5%) | before first round | – | unknown | D | 0% |
| 1 May 2015 | $5.34M | $1.94M – $14.7M | $5.59M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jun 2015 | $5.36M | $1.95M – $14.7M | $5.61M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jul 2015 | $5.38M | $1.96M – $14.8M | $5.64M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2015 | $5.40M | $1.97M – $14.8M | $5.78M (+7%) | before first round | – | unknown | D | 0% |
| 1 Sep 2015 | $5.42M | $1.97M – $14.9M | $5.94M (+10%) | before first round | – | unknown | D | 0% |
| 1 Oct 2015 | $5.44M | $1.98M – $14.9M | $6.09M (+12%) | before first round | – | unknown | D | 0% |
| 1 Nov 2015 | $5.46M | $1.99M – $15.0M | $6.26M (+15%) | before first round | – | unknown | D | 0% |
| 1 Dec 2015 | $5.48M | $2.00M – $15.1M | $6.42M (+17%) | before first round | – | unknown | D | 0% |
| 1 Jan 2016 | $5.51M | $2.00M – $15.1M | $6.60M (+20%) | before first round | – | unknown | D | 0% |
| 1 Feb 2016 | $5.53M | $2.01M – $15.2M | $6.78M (+23%) | before first round | – | unknown | D | 0% |
| 1 Mar 2016 | $5.55M | $2.02M – $15.2M | $6.95M (+25%) | before first round | – | unknown | D | 0% |
| 1 Apr 2016 | $5.57M | $2.03M – $15.3M | $7.14M (+28%) | before first round | – | unknown | D | 0% |
| 1 May 2016 | $5.59M | $2.04M – $15.4M | $7.33M (+31%) | before first round | – | unknown | D | 0% |
| 1 Jun 2016 | $5.61M | $2.04M – $15.4M | $7.53M (+34%) | before first round | – | unknown | D | 0% |
| 1 Jul 2016 | $5.64M | $2.05M – $15.5M | $7.72M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2016 | $5.79M | $2.11M – $15.9M | $7.93M (+37%) | before first round | – | unknown | D | 0% |
| 1 Sep 2016 | $5.94M | $2.16M – $16.3M | $8.15M (+37%) | before first round | – | unknown | D | 0% |
| 1 Oct 2016 | $6.10M | $2.22M – $16.8M | $8.36M (+37%) | before first round | – | unknown | D | 0% |
| 1 Nov 2016 | $6.26M | $2.28M – $17.2M | $8.59M (+37%) | before first round | – | unknown | D | 0% |
| 1 Dec 2016 | $6.43M | $2.34M – $17.7M | $8.81M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jan 2017 | $6.60M | $2.40M – $18.1M | $9.05M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2017 | $6.78M | $2.47M – $18.6M | $9.29M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2017 | $6.94M | $2.53M – $19.1M | $9.52M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2017 | $7.13M | $2.60M – $19.6M | $9.78M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2017 | $7.32M | $2.67M – $20.1M | $10.0M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2017 | $7.52M | $2.74M – $20.7M | $10.3M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2017 | $7.72M | $2.81M – $21.2M | $10.6M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2017 | $7.93M | $2.89M – $21.8M | $10.9M (+37%) | before first round | – | unknown | D | 0% |
| 1 Sep 2017 | $8.14M | $2.96M – $22.4M | $11.2M (+37%) | before first round | – | unknown | D | 0% |
| 1 Oct 2017 | $8.36M | $3.04M – $23.0M | $11.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Nov 2017 | $8.58M | $3.12M – $23.6M | $11.8M (+37%) | before first round | – | unknown | D | 0% |
| 1 Dec 2017 | $8.81M | $3.21M – $24.2M | $12.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jan 2018 | $9.05M | $3.29M – $24.9M | $12.4M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2018 | $9.29M | $3.38M – $25.5M | $12.7M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2018 | $9.52M | $3.47M – $26.2M | $13.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2018 | $9.78M | $3.56M – $26.9M | $13.4M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2018 | $10.0M | $3.65M – $27.6M | $13.8M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2018 | $10.3M | $3.75M – $28.3M | $14.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2018 | $10.6M | $3.85M – $29.1M | $14.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2018 | $10.9M | $3.96M – $29.9M | $14.7M (+35%) | before first round | – | unknown | D | 0% |
| 1 Sep 2018 | $11.2M | $4.06M – $30.7M | $14.8M (+32%) | before first round | – | unknown | D | 0% |
| 1 Oct 2018 | $11.5M | $4.17M – $31.5M | $14.9M (+30%) | before first round | – | unknown | D | 0% |
| 1 Nov 2018 | $11.8M | $4.28M – $32.3M | $15.1M (+28%) | before first round | – | unknown | D | 0% |
| 1 Dec 2018 | $12.1M | $4.40M – $33.2M | $15.2M (+26%) | before first round | – | unknown | D | 0% |
| 1 Jan 2019 | $12.4M | $4.52M – $34.1M | $15.3M (+24%) | before first round | – | unknown | D | 0% |
| 1 Feb 2019 | $12.7M | $4.64M – $35.0M | $15.5M (+21%) | before first round | – | unknown | D | 0% |
| 1 Mar 2019 | $13.1M | $4.75M – $35.9M | $15.6M (+19%) | before first round | – | unknown | D | 0% |
| 1 Apr 2019 | $13.4M | $4.88M – $36.8M | $15.7M (+17%) | before first round | – | unknown | D | 0% |
| 1 May 2019 | $13.8M | $5.01M – $37.8M | $15.9M (+15%) | before first round | – | unknown | D | 0% |
| 1 Jun 2019 | $14.1M | $5.15M – $38.8M | $16.0M (+13%) | before first round | – | unknown | D | 0% |
| 1 Jul 2019 | $14.5M | $5.28M – $39.8M | $16.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2019 | $14.7M | $5.33M – $40.2M | $16.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2019 | $14.8M | $5.38M – $40.6M | $16.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2019 | $14.9M | $5.43M – $41.0M | $16.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2019 | $15.1M | $5.48M – $41.4M | $16.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2019 | $15.2M | $5.53M – $41.7M | $16.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2020 | $15.3M | $5.58M – $42.1M | $17.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2020 | $15.5M | $5.63M – $42.5M | $17.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2020 | $15.6M | $5.68M – $42.9M | $17.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2020 | $15.7M | $5.73M – $43.3M | $17.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2020 | $15.9M | $5.78M – $43.6M | $17.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2020 | $16.0M | $5.84M – $44.0M | $17.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jul 2020 | $16.2M | $5.89M – $44.4M | $18.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2020 | $16.3M | $5.94M – $44.8M | $18.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2020 | $16.5M | $6.00M – $45.2M | $18.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2020 | $16.6M | $6.05M – $45.6M | $18.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2020 | $16.8M | $6.11M – $46.1M | $18.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2020 | $16.9M | $6.16M – $46.5M | $18.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2021 | $17.1M | $6.21M – $46.9M | $19.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2021 | $17.2M | $6.27M – $47.3M | $19.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2021 | $17.4M | $6.32M – $47.7M | $19.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2021 | $17.5M | $6.38M – $48.2M | $19.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2021 | $17.7M | $6.44M – $48.6M | $19.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2021 | $17.8M | $6.50M – $49.0M | $19.7M (+10%) | before first round | – | unknown | D | 0% |
| 1 Jul 2021 | $18.0M | $6.56M – $49.5M | $19.9M (+10%) | before first round | – | unknown | D | 0% |
| 28 Jul 2021 | $722M | $475M – $1.2B | $794M (+10%) | after a round | – | unknown | B | 0% |
| 1 Aug 2021 | $723M | $475M – $1.2B | $794M (+10%) | after a round | – | unknown | B | 0% |
| 1 Sep 2021 | $729M | $475M – $1.2B | $794M (+9%) | after a round | – | unknown | B | 0% |
| 1 Oct 2021 | $735M | $475M – $1.2B | $794M (+8%) | after a round | – | unknown | B | 0% |
| 1 Nov 2021 | $741M | $475M – $1.2B | $794M (+7%) | after a round | – | unknown | B | 0% |
| 1 Dec 2021 | $747M | $475M – $1.2B | $794M (+6%) | after a round | – | unknown | B | 0% |
| 1 Jan 2022 | $753M | $475M – $1.2B | $794M (+6%) | after a round | – | unknown | B | 0% |
| 1 Feb 2022 | $759M | $475M – $1.2B | $794M (+5%) | after a round | – | unknown | B | 0% |
| 1 Mar 2022 | $764M | $475M – $1.2B | $794M (+4%) | after a round | – | unknown | B | 0% |
| 1 Apr 2022 | $771M | $475M – $1.2B | $794M (+3%) | after a round | 80 | unknown | B | 0% |
| 1 May 2022 | $777M | $475M – $1.2B | $794M (+2%) | after a round | 80 | unknown | B | 0% |
| 1 Jun 2022 | $783M | $475M – $1.2B | $794M (+1%) | after a round | 80 | unknown | B | 0% |
| 1 Jul 2022 | $789M | $475M – $1.2B | $794M (+1%) | after a round | 80 | unknown | B | 0% |
| 1 Aug 2022 | $794M | $471M – $1.2B | $794M (0%) | after a round | 80 | unknown | B | 0% |
| 1 Sep 2022 | $794M | $447M – $1.2B | $794M (0%) | after a round | 80 | unknown | B | 0% |
| 1 Oct 2022 | $794M | $426M – $1.2B | $794M (0%) | after a round | 80 | unknown | B | 0% |
| 1 Nov 2022 | $794M | $405M – $1.2B | $794M (0%) | after a round | 80 | unknown | B | 0% |
| 1 Dec 2022 | $794M | $385M – $1.2B | $794M (0%) | after a round | 80 | unknown | B | 0% |
| 1 Jan 2023 | $794M | $366M – $1.2B | $794M (0%) | after a round | 85 | flat | B | 0% |
| 1 Feb 2023 | $794M | $348M – $1.2B | $794M (0%) | after a round | 85 | flat | C | 0% |
| 1 Mar 2023 | $794M | $332M – $1.2B | $794M (0%) | after a round | 85 | flat | C | 0% |
| 1 Apr 2023 | $794M | $316M – $1.2B | $794M (0%) | after a round | 85 | flat | C | 0% |
| 1 May 2023 | $794M | $301M – $1.2B | $794M (0%) | after a round | 85 | flat | C | 0% |
| 1 Jun 2023 | $794M | $286M – $1.2B | $794M (0%) | after a round | 85 | flat | C | 0% |
| 1 Jul 2023 | $794M | $272M – $1.2B | $794M (0%) | after a round | 85 | flat | C | 0% |
| 1 Aug 2023 | $794M | $259M – $1.2B | $794M (0%) | after a round | 85 | flat | C | 0% |
| 1 Sep 2023 | $794M | $246M – $1.2B | $788M (-1%) | after a round | 85 | flat | C | 0% |
| 1 Oct 2023 | $794M | $294M – $1.2B | $785M (-1%) | after a round | 89 | up | C | 0% |
| 1 Nov 2023 | $794M | $222M – $1.2B | $777M (-2%) | after a round | 89 | flat | C | 0% |
| 1 Dec 2023 | $794M | $212M – $1.2B | $771M (-3%) | after a round | 89 | flat | C | 0% |
| 1 Jan 2024 | $794M | $201M – $1.2B | $766M (-4%) | after a round | 89 | flat | C | 0% |
| 1 Feb 2024 | $794M | $191M – $1.2B | $760M (-4%) | after a round | 89 | flat | C | 0% |
| 1 Mar 2024 | $794M | $248M – $1.2B | $765M (-4%) | after a round | 95 | up | C | 0% |
| 1 Apr 2024 | $794M | $240M – $1.2B | $760M (-4%) | after a round | 95 | up | C | 0% |
| 1 May 2024 | $794M | $232M – $1.2B | $756M (-5%) | after a round | 95 | up | C | 0% |
| 1 Jun 2024 | $794M | $224M – $1.2B | $752M (-5%) | after a round | 95 | up | C | 0% |
| 1 Jul 2024 | $794M | $217M – $1.2B | $748M (-6%) | after a round | 95 | up | C | 0% |
| 1 Aug 2024 | $794M | $176M – $1.2B | $771M (-3%) | after a round | 110 | up | C | 0% |
| 1 Sep 2024 | $792M | $168M – $1.2B | $769M (-3%) | after a round | 110 | up | C | 0% |
| 1 Oct 2024 | $790M | $161M – $1.2B | $767M (-3%) | after a round | 110 | up | D | 0% |
| 1 Nov 2024 | $790M | $155M – $1.2B | $773M (-2%) | after a round | 110 | up | D | 0% |
| 1 Dec 2024 | $789M | $148M – $1.2B | $772M (-2%) | after a round | 110 | up | D | 0% |
| 1 Jan 2025 | $787M | $142M – $1.2B | $770M (-2%) | after a round | 110 | up | D | 0% |
| 1 Feb 2025 | $786M | $136M – $1.2B | $769M (-2%) | after a round | 110 | up | D | 0% |
| 1 Mar 2025 | $784M | $131M – $1.2B | $768M (-2%) | after a round | 110 | up | D | 0% |
| 1 Apr 2025 | $783M | $126M – $1.2B | $766M (-2%) | after a round | 110 | up | D | 0% |
| 1 May 2025 | $766M | $121M – $1.2B | $730M (-5%) | after a round | 110 | up | D | 0% |
| 1 Jun 2025 | $763M | $116M – $1.2B | $727M (-5%) | after a round | 110 | up | D | 0% |
| 1 Jul 2025 | $774M | $111M – $1.2B | $753M (-3%) | after a round | 120 | up | D | 0% |
| 1 Aug 2025 | $774M | $118M – $1.2B | $754M (-3%) | after a round | 122 | up | D | 0% |
| 1 Sep 2025 | $772M | $114M – $1.2B | $752M (-3%) | after a round | 122 | up | D | 0% |
| 1 Oct 2025 | $743M | $110M – $1.1B | $722M (-3%) | after a round | 124 | up | D | 0% |
| 1 Nov 2025 | $740M | $105M – $1.1B | $722M (-2%) | after a round | 124 | up | D | 0% |
| 1 Dec 2025 | $736M | $101M – $1.1B | $722M (-2%) | after a round | 124 | up | D | 0% |
| 1 Jan 2026 | $733M | $97.4M – $1.1B | $722M (-1%) | after a round | 124 | up | D | 0% |
| 1 Feb 2026 | $729M | $93.6M – $1.1B | $722M (-1%) | after a round | 124 | up | D | 0% |
| 1 Mar 2026 | $723M | $90.3M – $1.1B | $722M (0%) | after a round | 124 | up | D | 0% |
| 1 Apr 2026 | $738M | $86.8M – $1.1B | $722M (-2%) | after a round | 130 | up | D | 0% |
| 1 May 2026 | $731M | $83.5M – $1.1B | $722M (-1%) | after a round | 128 | up | D | 0% |
| 19 May 2026 | $16.7B | $11.0B – $27.9B | $18.3B (+10%) | after a round | 128 | flat | B | 0% |
| 1 Jun 2026 | $16.7B | $11.0B – $27.9B | $18.3B (+10%) | after a round | 128 | flat | B | 0% |
| 1 Jul 2026 | $16.9B | $11.0B – $27.9B | $18.3B (+9%) | after a round | 128 | flat | B | 0% |
| 1 Aug 2026 | $17.0B | $11.0B – $27.9B | $18.3B (+8%) | after a round | 128 | flat | B | 0% |
| 1 Sep 2026 | $17.1B | $11.0B – $27.9B | $18.3B (+7%) | after a round | 128 | flat | B | 0% |
| 1 Oct 2026 | $17.3B | $11.1B – $28.2B | $18.5B (+7%) | after a round | 135 | up | B | 0% |
| 24 Oct 2026 | $17.5B | $11.1B – $28.2B | $18.5B (+6%) | after a round | 135 | up | B | 0% |
Key facts about MiRus
- Founded
- 2015
- Headquarters
- Marietta, United States
- Employees
- about 135 +9% in a year
- Total raised
- $1.56B
- Funding rounds
- 2
- Last round
- Growth Equity May 2026
MiRus was founded in 2015 by Jay Yadav.
MiRus funding history
MiRus has 2 funding rounds on record, from Jul 2021 to May 2026, $1.56B in total. None disclosed a valuation.
Growth Equity 18 May 2026
Led by Boston Scientific Corporation.
Sources: mirusmed.com, news.bostonscientific.com, prnewswire.com and 3 more
$1.50B
Growth Equity 27 Jul 2021
Led by Mammoth Scientific; with multi-generational family offices. Individuals: Jay Yadav.
Sources: prnewswire.com, mammoth.vc, beckersspine.com and 1 more
$65M
MiRus investors
3 investors have backed MiRus; Boston Scientific Corporation and Mammoth Scientific led at least one round.
- Boston Scientific Corporation lead
- Mammoth Scientific lead
- multi-generational family offices
What MiRus does
MiRus works in medical supply manufacturers, with 11 recorded offerings and customers in healthcare, medical devices, cardiovascular and orthopedics.
MiRus, LLC is an American medical device company engaged in the development and manufacturing of medical devices and procedural solutions for the treatment of spine, orthopedic, and structural heart diseases. The company also provides remote physiologic monitoring systems and conducts clinical research and development. MiRus serves healthcare professionals and medical institutions, with products approved by the FDA.
Description from Veridion's company data.
Products and services
- Medical Device Development and Manufacturing
- Spine and Orthopedic Implant Manufacturing
- Structural Heart Implant Manufacturing
- Proprietary Alloy Technology Development
- Advanced Implant Design Engineering
- Procedural Solution Development
- Remote Physiologic Monitoring System Development
- Clinical Trial Execution Services
- Surgeon and Medical Institution Collaboration Services
- Patient Outcome Enhancement Solutions
- Continuum of Care Technology Solutions
Markets
- Healthcare
- Medical Devices
- Cardiovascular
- Orthopedics
Technology
- Rhenium-Based Alloy Technology
Certifications
- FDA certified
Business model
- Business-to-Business
- Manufacturing
Industry codes (NAICS)
- 339113 Surgical Appliance and Supplies Manufacturing 100% match
Questions about MiRus
What is MiRus worth?
Valuation $17.5B (range $11.1B to $28.2B), as of 24 Oct 2026.
Has MiRus raised money?
MiRus has 2 funding rounds on record, from Jul 2021 to May 2026, $1.56B in total. None disclosed a valuation.
Who has invested in MiRus?
Boston Scientific Corporation, Mammoth Scientific and multi-generational family offices. Lead investors include Boston Scientific Corporation and Mammoth Scientific.
How many people work at MiRus?
About 135, up 9% over the last year. Headcount grew from 80 in Apr 2022 to 135 in Sep 2026.
What does MiRus do?
MiRus works in medical supply manufacturers, with 11 recorded offerings and customers in healthcare, medical devices, cardiovascular and orthopedics. Its main offerings are medical device development and manufacturing, spine and orthopedic implant manufacturing and structural heart implant manufacturing.
When was MiRus founded, and where is it based?
MiRus was founded in 2015 and is based in Marietta, United States. It has about 135 employees, up 9% over the last year.